Fig. 4

Toxicity of the combined treatment of prostate cancer comprising simultaneous application of 1,4-DMP and docetaxel (DTX). a Survival of BALB/c Nude mice bearing PC-3 M-luc2 tumors, treated with docetaxel (DTX) and 1,4-DMP either alone or in combination. b Body weight of BALB/c Nude mice bearing PC-3M-luc2 tumors, treated with docetaxel (DTX) and 1,4-DMP either alone or in combination. In graphs a and b, days of drug administration are indicated with gray arrows for docetaxel (DTX) and dotted arrow for 1,4-DMP. c Red blood cell (RBC) count (*p < 0.05 vs. 14-DMP; **p < 0.05 vs. control and 1,4-DMP); and d hemoglobin concentration in blood samples taken from BALB/c Nude mice bearing PC-3M-luc2 tumors on the last day of the experiment (day 46). Plasma concentrations of: e creatinine (*p < 0.05 vs. control and 1,4-DMP) and f urea (*p < 0.05 vs. control and 1,4-DMP) determined for plasma samples obtained from BALB/c Nude mice bearing PC-3M-luc2 tumors on the last day of the experiment (day 46). The activity of: g lactate dehydrogenase (LDH) (*p < 0.05 vs. control, DTX and 1,4-DMP); h aspartate aminotransferase (AST) (*p < 0.05 vs. control, DTX and 1,4-DMP); and i alanine aminotransferase (ALT) (*p < 0.05 vs. control and 1,4-DMP) determined in blood plasma samples obtained from BALB/c Nude mice bearing PC-3 M-luc2 tumors on the last day of the experiment (day 46). All data are presented as mean ± SD values